Blood Pressure Reduction With Dapagliflozin in Patients With Type 2 Diabetes and Cardiovascular Disease

被引：0
|
作者：
Woo, Vincent [1 ]
Leiter, Lawrence A. [2 ]
Cefalu, William T. [3 ]
de Bruin, Tjerk W. [4 ]
Gause-Nilsson, Ingrid [5 ]
Parikh, Shamik J. [4 ]
Johnsson, Eva [5 ]
机构：
[1] Univ Manitoba, Endocrinol Sect, Winnipeg, MB, Canada
[2] St Michaels Hosp, Div Endocrinol & Metab, Toronto, ON M5B 1W8, Canada
[3] Louisiana State Univ Syst, Pennington Biomed Rsch Cntr, Baton Rouge, LA USA
[4] AstraZeneca, Rsch & Dev, Wilmington, DE USA
[5] AstraZeneca, Rsch & Dev, Molndal, Sweden
来源：
CIRCULATION | 2013年 / 128卷 / 22期
关键词：
Blood pressure; Cardiovascular disease; Clinical trials; Diuretics; Older population;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
10606
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Proteinuria modifies the effect of systolic blood pressure on total and cardiovascular disease mortality in patients with type 2 diabetes
    Vepsalainen, T.
    Laakso, M.
    Kantola, I.
    Lehto, S.
    Juutilainen, A.
    Ronnemaa, T.
    [J]. JOURNAL OF INTERNAL MEDICINE, 2012, 272 (06) : 611 - 619
  • [32] Comparison of cardiovascular and renal outcomes between dapagliflozin and empagliflozin in patients with type 2 diabetes without prior cardiovascular or renal disease
    Lim, Jayoung
    Hwang, In-Chang
    Choi, Hong-Mi
    Yoon, Yeonyee E.
    Cho, Goo-Yeong
    [J]. PLOS ONE, 2022, 17 (10):
  • [33] Pulse Pressure Predicts Future Cardiovascular Events in Cardiovascular Disease Patients with Type 2 Diabetes
    Plattner, Thomas
    Vonbank, Alexander
    Mader, Arthur
    Sprenger, Lukas
    Maechler, Maximilian
    Larcher, Barbara
    Leiherer, Andreas
    Muendlein, Axel
    Drexel, Heinz
    Saely, Christoph H.
    [J]. DIABETES, 2023, 72
  • [34] Cardiovascular disease in patients with type 2 diabetes
    Jeon, Ja Young
    Kim, Dae Jung
    [J]. JOURNAL OF DIABETES INVESTIGATION, 2022, 13 (04) : 614 - 616
  • [35] Pulse Pressure Predicts Future Cardiovascular Events in Cardiovascular Disease Patients with Type 2 Diabetes
    Plattner, Thomas
    Vonbank, Alexander
    Mader, Arthur
    Sprenger, Lukas
    Maechler, Maximilian
    Larcher, Barbara
    Leiherer, Andreas
    Muendlein, Axel
    Drexel, Heinz
    Saely, Christoph
    [J]. WIENER KLINISCHE WOCHENSCHRIFT, 2023, 135 : S773 - S774
  • [36] Two-year efficacy and safety of dapagliflozin for patients with type 2 diabetes mellitus and a history of cardiovascular disease
    Gause-Nilsson, I.
    DeBruin, T. W.
    Sugg, J.
    Parikh, S. J.
    Johnsson, E.
    Leiter, L. A.
    [J]. DIABETOLOGIA, 2014, 57 : S325 - S325
  • [37] THE EFFECT OF DAPAGLIFLOZIN ON THE LEVEL OF SYSTOLIC BLOOD PRESSURE AND GLYCEMIC CONTROL IN PATIENTS WITH ARTERIAL HYPERTENSION AND TYPE 2 DIABETES
    Zhuravlyova, Larysa
    Rogachova, Tetyana
    Sokolnikova, Nelya
    Filonenko, Maryna
    [J]. JOURNAL OF HYPERTENSION, 2022, 40 (SUPPL) : E184 - E184
  • [38] Reductions in HbA1c and Systolic Blood Pressure in Patients with Type 2 Diabetes Treated with Dapagliflozin
    Moran, Jason
    Katz, Arie
    Yeh, Helen
    [J]. DIABETES, 2015, 64 : A309 - A309
  • [39] Dapagliflozin Does Not Affect Short-Term Blood Pressure Variability in Patients With Type 2 Diabetes Mellitus
    Papadopoulou, Eirini
    Theodorakopoulou, Marieta P.
    Loutradis, Charalampos
    Tzanis, Georgios
    Tzatzagou, Glykeria
    Kotsa, Kalliopi
    Zografou, Ioanna
    Tsapas, Apostolos
    Karagiannis, Asterios
    Sarafidis, Pantelis
    [J]. AMERICAN JOURNAL OF HYPERTENSION, 2021, 34 (04) : 404 - 413
  • [40] Control of blood pressure and cardiovascular outcomes in type 2 diabetes
    Vargas-Uricoechea, Hernando
    Felipe Caceres-Acosta, Manuel
    [J]. OPEN MEDICINE, 2018, 13 (01): : 304 - 323
12345